ANDAINTRAVENOUSSOLUTION
Approved
Feb 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NEOSTIGMINE METHYLSULFATE (neostigmine methylsulfate) by Sagent Pharmaceuticals is 12. First approved in 2023.
Drug data last refreshed 21h ago
Mechanism of Action
12.1. Mechanism of Action Neostigmine methylsulfate is a competitive cholinesterase inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as non-depolarizing neuromuscular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Sagent Pharmaceuticals
Worked on NEOSTIGMINE METHYLSULFATE at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.